Wells Fargo & Co upgraded shares of Gilead Sciences (NASDAQ:GILD) from a market perform rating to an outperform rating in a research report report published on Tuesday morning, MarketBeat reports. They currently have $96.00 target price on the biopharmaceutical company’s stock, up from their prior target price of $79.02.

Several other equities research analysts have also weighed in on GILD. Mizuho restated a buy rating on shares of Gilead Sciences in a report on Friday, September 29th. BidaskClub lowered Gilead Sciences from a hold rating to a sell rating in a report on Tuesday, January 9th. BMO Capital Markets restated a hold rating on shares of Gilead Sciences in a report on Wednesday, January 3rd. Credit Suisse Group set a $80.00 target price on Gilead Sciences and gave the stock a hold rating in a report on Wednesday, January 3rd. Finally, Maxim Group restated a hold rating on shares of Gilead Sciences in a report on Thursday, October 19th. One research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of Buy and an average target price of $85.61.

Gilead Sciences (NASDAQ GILD) traded up $1.49 on Tuesday, reaching $81.74. The company had a trading volume of 11,162,626 shares, compared to its average volume of 8,682,218. Gilead Sciences has a 12-month low of $63.76 and a 12-month high of $86.27. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The firm has a market cap of $106,750.00, a price-to-earnings ratio of 9.30, a P/E/G ratio of -1.68 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. During the same period in the previous year, the company earned $2.75 EPS. The company’s revenue for the quarter was down 13.2% on a year-over-year basis. research analysts expect that Gilead Sciences will post 8.53 EPS for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were paid a $0.52 dividend. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.54%. Gilead Sciences’s payout ratio is 23.66%.

In related news, EVP Gregg H. Alton sold 30,000 shares of the company’s stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $79.00, for a total value of $2,370,000.00. Following the completion of the transaction, the executive vice president now directly owns 57,114 shares in the company, valued at $4,512,006. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the company’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. Insiders sold 491,666 shares of company stock valued at $36,442,567 over the last 90 days. 1.30% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Welch Investments LLC bought a new stake in Gilead Sciences in the third quarter valued at $108,000. Wealthcare Advisory Partners LLC bought a new stake in Gilead Sciences in the third quarter valued at $133,000. Horan Capital Advisors LLC. bought a new stake in Gilead Sciences in the third quarter valued at $144,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Gilead Sciences in the second quarter valued at $147,000. Finally, Hanson & Doremus Investment Management grew its position in Gilead Sciences by 806.5% in the third quarter. Hanson & Doremus Investment Management now owns 1,813 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 1,613 shares during the period. Institutional investors and hedge funds own 75.95% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Gilead Sciences (GILD) Stock Rating Upgraded by Wells Fargo & Co” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally stolen and republished in violation of United States & international copyright & trademark legislation. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/17/gilead-sciences-gild-stock-rating-upgraded-by-wells-fargo-co.html.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related stocks with our FREE daily email newsletter.